A multifunctional bispecific antibody against Pseudomonas aeruginosa as a potential therapeutic strategy

Pseudomonas aeruginosa (P. aeruginosa) is a Gram-negative bacteria that is responsible for significant morbidity and mortality in human populations (1). It is a common cause of hospital-acquired and ventilator-associated pneumonia, opportunistic infections in immunosuppressed and burns patients, and most notably a frequent and troublesome bacteria in the airway of people with cystic fibrosis (1,2).